Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Carmelo Tibaldi"'
Autor:
Marzia Del Re, Giovanna Irene Luculli, Iacopo Petrini, Andrea Sbrana, Vieri Scotti, Diego de Miguel Perez, Lorenzo Livi, Stefania Crucitta, Mauro Iannopollo, Francesca Mazzoni, Martina Ruglioni, Carmelo Tibaldi, Emanuela Olmetto, Irene Stasi, Editta Baldini, Giacomo Allegrini, Lorenzo Antonuzzo, Franco Morelli, Andrea Pierini, Nicola Panzeri, Stefano Fogli, Antonio Chella, Christian Rolfo, Romano Danesi
Publikováno v:
Translational Oncology, Vol 41, Iss , Pp 101869- (2024)
Background: The present study evaluates the utility of NGS analysis of circulating free DNA (cfDNA), which incorporates small amounts of tumor DNA (ctDNA), at diagnosis or at disease progression (PD) in NSCLC patients. Methods: Comprehensive genomic
Externí odkaz:
https://doaj.org/article/262397be030b4702b3e34b61b234daba
Autor:
Andrea Camerini, Francesca Mazzoni, Vieri Scotti, Carmelo Tibaldi, Andrea Sbrana, Luana Calabrò, Enrico Caliman, Lucia Pia Ciccone, Laura Bernardini, Jessica Graziani, Maria Antonietta Grosso, Antonio Chella, Giacomo Allegrini, Domenico Amoroso, Editta Baldini
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 13, p 3642 (2024)
Background: There are currently few data about the safety and effectiveness of chemotherapy for patients with metastatic non-small-cell lung cancer (NSCLC) who have progressed from prior immunotherapy. Methods: Data from patients with consecutive sta
Externí odkaz:
https://doaj.org/article/3fdb383b40304addad5a6516fec29e93
Autor:
Richard J. Honeywell, Ietje Kathmann, Elisa Giovannetti, Carmelo Tibaldi, Egbert F. Smit, Maria N. Rovithi, Henk M.W. Verheul, Godefridus J. Peters
Publikováno v:
Cancers, Vol 12, Iss 11, p 3322 (2020)
Background: tyrosine kinase inhibitors (TKIs) inhibit phosphorylation of signaling proteins. TKIs often show large variations in the clinic due to poor pharmacology, possibly leading to resistance. We compared gut absorption of inhibitors of epiderma
Externí odkaz:
https://doaj.org/article/c64ca7a182124f588213d5b3d615e9f8
Autor:
Vieri Scotti, Beatrice Fantechi, Francesca Mazzoni, I. Stasi, Irene Pecora, Carmelo Tibaldi, Enrico Vasile, Chiara Caparello, Editta Baldini, Marianna Turrini, Lorenzo Antonuzzo, Francesca Federici, Andrea Camerini, Giulia Meoni, Daniele Pozzessere, Diana Giannarelli, Virginia Rossi, L.P. Ciccone
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1278-1285
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe. Objective: To evaluate retrospectively the safety and efficacy of this drug and to
Publikováno v:
Global Journal of Cancer Case Reports.
Publikováno v:
Precision Cancer Medicine. 5:6-6
Autor:
Carmelo Tibaldi, Editta Baldini
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 145
Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 22(10)
Approximately one-third of all non-small-cell lung cancer (NSCLC) are locally-advanced at diagnosis, and 15–17% of these tumors are unresectable at presentation. Definitive chemo-radiotherapy (CRT) represents the standard therapeutic approach. Howe
Autor:
Giovanni Luca Ceresoli, Barbara Melotti, Diego Signorelli, Francesco Verderame, Alice Lunghi, Vieri Scotti, Enrico Cortesi, Giacomo Cartenì, Daniele Turci, Gianpiero Fasola, Enrico Ricevuto, Paolo Marchetti, Carmelo Tibaldi, Alfonso Illiano, Luisa Fioretto, Diana Giannarelli, Editta Baldini, Antonio Frassoldati, Carmine Pinto, Biagio Ricciuti, Giampiero Romano, Valeria Stati
Objectives The incidence of any and of severe-grade immune-related adverse events (irAEs) with second-line nivolumab monotherapy is 31–65 % and 2–5 % respectively. While potentially serious and even fatal, in the absence of an appropriate therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a28894fc3abc7f2350fa495f0a094b05
http://hdl.handle.net/11392/2418755
http://hdl.handle.net/11392/2418755
Autor:
Chiara Catania, Godefridus J. Peters, Elisa Giovannetti, Lorenzo Spaggiari, Giuseppe Pelosi, Lars Petter Jordheim, Davide Radice, Michela Manzotti, Mariacarmela Santarpia, Francesca Toffalorio, Filippo de Braud, Gianluca Spitaleri, Niccola Funel, Carmelo Tibaldi, Tommaso De Pas, Christopher Adrian Jaramillo
Publikováno v:
Oncotarget
Oncotarget, 9(23), 16437-16450. Impact Journals
Oncotarget 9 (2018): 16437–16450. doi:10.18632/oncotarget.24505
info:cnr-pdr/source/autori:Toffalorio F.; Santarpia M.; Radice D.; Jaramillo C.A.; Spitaleri G.; Manzotti M.; Catania C.; Jordheim L.P.; Pelosi G.; Peters G.J.; Tibaldi C.; Funel N.; Spaggiari L.; de Braud F.; De Pas T.; Giovannetti E./titolo:5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine%2Fplatinum combination chemotherapy in non-small cell lung cancer/doi:10.18632%2Foncotarget.24505/rivista:Oncotarget/anno:2018/pagina_da:16437/pagina_a:16450/intervallo_pagine:16437–16450/volume:9
Toffalorio, F, Santarpia, M, Radice, D, Jaramillo, C A, Spitaleri, G, Manzotti, M, Catania, C, Jordheim, L P, Pelosi, G, Peters, G J, Tibaldi, C, Funel, N, Spaggiari, L, de Braud, F, de Pas, T & Giovannetti, E 2018, ' 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer ', Oncotarget, vol. 9, no. 23, pp. 16437-16450 . https://doi.org/10.18632/oncotarget.24505
Oncotarget, 9(23), 16437-16450. Impact Journals
Oncotarget 9 (2018): 16437–16450. doi:10.18632/oncotarget.24505
info:cnr-pdr/source/autori:Toffalorio F.; Santarpia M.; Radice D.; Jaramillo C.A.; Spitaleri G.; Manzotti M.; Catania C.; Jordheim L.P.; Pelosi G.; Peters G.J.; Tibaldi C.; Funel N.; Spaggiari L.; de Braud F.; De Pas T.; Giovannetti E./titolo:5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine%2Fplatinum combination chemotherapy in non-small cell lung cancer/doi:10.18632%2Foncotarget.24505/rivista:Oncotarget/anno:2018/pagina_da:16437/pagina_a:16450/intervallo_pagine:16437–16450/volume:9
Toffalorio, F, Santarpia, M, Radice, D, Jaramillo, C A, Spitaleri, G, Manzotti, M, Catania, C, Jordheim, L P, Pelosi, G, Peters, G J, Tibaldi, C, Funel, N, Spaggiari, L, de Braud, F, de Pas, T & Giovannetti, E 2018, ' 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer ', Oncotarget, vol. 9, no. 23, pp. 16437-16450 . https://doi.org/10.18632/oncotarget.24505
// Francesca Toffalorio 1, 2, * , Mariacarmela Santarpia 1, 3, * , Davide Radice 4 , Christopher Adrian Jaramillo 5 , Gianluca Spitaleri 1, 6 , Michela Manzotti 7 , Chiara Catania 1, 6 , Lars Petter Jordheim 8 , Giuseppe Pelosi 9, 10 , Godefridus J.